Home/Filings/4/0001193125-25-317551
4//SEC Filing

LEONARD JOHN M 4

Accession 0001193125-25-317551

CIK 0001652130other

Filed

Dec 11, 7:00 PM ET

Accepted

Dec 12, 4:09 PM ET

Size

16.9 KB

Accession

0001193125-25-317551

Insider Transaction Report

Form 4
Period: 2025-12-11
LEONARD JOHN M
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-11$6.83/sh+49,959$341,2201,127,074 total
  • Sale

    Common Stock

    2025-12-11$9.49/sh49,959$474,1111,077,115 total
  • Sale

    Common Stock

    2025-12-11$9.47/sh32,832$310,9191,044,283 total
  • Sale

    Common Stock

    2025-12-11$9.59/sh5,355$51,3541,038,928 total
  • Exercise/Conversion

    Common Stock

    2025-12-12$6.83/sh+8,557$58,4441,047,485 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-12-1149,9598,557 total
    Exercise: $6.83Exp: 2026-02-03Common Stock (49,959 underlying)
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-12-128,5570 total
    Exercise: $6.83Exp: 2026-02-03Common Stock (8,557 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    58,415
Footnotes (6)
  • [F1]The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.
  • [F5]Shares held by the John M. Leonard 2015 Irrevocable Trust.
  • [F6]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025.

Documents

1 file

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1
  • filerCIK 0001563584

Filing Metadata

Form type
4
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 4:09 PM ET
Size
16.9 KB